Alnylam Pharmaceuticals

alnylam.com

Alnylam Pharmaceuticals is a pioneering biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, which silence genes responsible for various diseases. Founded in 2002, Alnylam has developed five approved RNAi medicines, including ONPATTRO® and GIVLAARI®, targeting rare and prevalent diseases. The company is committed to addressing high unmet medical needs through innovative therapies, leveraging Nobel Prize-winning science to disrupt disease at its genetic source. With a robust pipeline and a focus on patient-centric solutions, Alnylam is positioned as a leader in the RNAi therapeutics market, aiming to improve the lives of millions globally.